Fibrosing interstitial lung diseases of idiopathic and exogenous origin. Phenotype approach.

Conference and Postgradual Course

hosted by
CZECH PNEUMOLOGICAL
AND PHthisEOLOGICAL SOCIETY

chaired by
PROF. VENERINO POLETTI AND
ASSOC PROF. MARTINA VAŠÁKOVÁ

PRAGUE
CZECH REPUBLIC
JUNE 19TH – 21ST 2014
HOTEL ARTEMIS
U SLUNCOVÉ 14, PRAGUE 8

THE CONFERENCE IS HELD UNDER THE AUSPICES OF:
WORLD ASSOCIATION OF SARCOIDOSIS AND OTHER GRANULOMATOUS DISORDERS
ITALIAN ASSOCIATION OF HOSPITAL PNEUMOLOGY (AIPO)

THE CONFERENCE HAS ENDORSEMENT OF EUROPEAN RESPIRATORY SOCIETY
General Sponsor

INTErmUNE®
Leader in IPF

INFORMATION

Organising committee:
Assoc. Prof. Martina Vasakova, MD, PhD, Prague, Czech Republic
Prof. Venerino Poletti, MD, FCCP, Forli, Italy
Assist. Prof. Martina Stercova, MD, PhD, Prague, Czech Republic

Registration:
Opened from 1 Dec 2013,
online www.ildprague2014.com
Registration fee: 100 EUR (early bird- up to 31 Mar 2014),
150 EUR (after 31 Mar 2014)
Payment: Bank transfer, Card

Accommodation:
Olympik Hotel: www.olympik.cz/en/olympik
Tristar Hotel: www.olympik.cz/en/tristar

Social events:
Thursday 19 Jun: Dinner at restaurant Vikarka
Friday 20 Jun: Sightseeing tour around Prague

Call for abstracts:
All participants are encouraged to send an abstract addressing
different aspects of fibrosing interstitial lung diseases. The abstracts
will be accepted for poster presentation. Posters will be displayed
during the whole conference and discussed by faculty members on
Friday. There will be award for the best three posters announced on
the last day of the conference.
The abstracts are to be submitted electronically:
www.ildprague2014.com
Deadline for abstract submission: 31 Mar 2014
Structure of abstract: maximal extent: 300 words,
recommended structure: Aims, Methods, Results, Conclusions
7:30 – 8:15  Registration
8:15  Opening ceremony. Address of Organizers, Presidents of CPFS, AIPO and WASOG

Session I – Epidemiology and Classification of Interstitial lung diseases
Chairs: Wells A., Camus P., Costabel U.

8:30 – 8:55  Epidemiology and Classification of Idiopathic interstitial pneumonias.
Wells A. (20 min + 5 min Discussion)

8:55 – 9:20  Epidemiology and Classification of Hypersensitivity Pneumonitis.
Costabel U. (20 min + 5 min Discussion)

9:20 – 9:45  Epidemiology and Classification of Pneumoconioses.
Cordeiro CR. (20 min + 5 min Discussion)

9:45 – 10:10  Epidemiology and Classification of smoking related interstitial lung diseases.
Šterclová M. (20 min + 5 min Discussion)

10:10 – 10:35  Epidemiology and Classification of drug-related interstitial lung diseases.
Camus P. (20 min + 5 min Discussion)

10:35 – 11:00  Coffee Break

Session II – Pathogenesis of Interstitial lung diseases
Chairs: Crestani B., Dottorini M., Nemery B.

11:00 – 11:25  Pathogenesis of idiopathic pulmonary fibrosis.
Chilosi M. (20 min + 5 min Discussion)

Crestani B. (20 min + 5 min Discussion)

11:50 – 12:15  Potential role of exogenous particles, gasses and fumes in pathogenesis of „idiopathic“ interstitial lung diseases. Does air pollution contribute to epidemiology of idiopathic ILDs?
Nemery B. (20 min + 5 min Discussion)

12:15 – 12:40  Pathogenesis of hypersensitivity pneumonitis.
Antoniou K. (20 min + 5 min Discussion)

Cordeiro CR. (20 min + 5 min Discussion)

Camus P. (20 min + 5 min Discussion)

13:30 – 14:30  Lunch

Session III – Practical/workshops – different HRCT patterns in ILDs- in which ILDs can we find them and how can we identify them?
Chairs: Heussel CP., Sverzellati N.

14:30 – 14:50  UIP pattern.
Sverzellati N.

14:50 – 15:10  NSIP pattern.
Heussel CP.

15:10 – 15:30  AIP and OP pattern.
Sverzellati N.

15:30 – 15:50  Radiological image of LIP and other rare ILDs.
Heussel CP.

www.ildprague2014.com
15:50 – 16:20 Radiological case reports. Interactive session with voting of audience.  
Sverzellati N., Heussel CP.

16:20 – 16:45 Coffee Break

Session IV – Practical/workshops – different histopathological patterns in ILDs- does one pattern mean one clinical diagnosis?  
Chairs: Colby T., Matěj R.

16:45 – 17:05 What does lung fibrosis mean from the pathologist’s point of view? Which patterns of fibrotic changes can we find in different ILDs?  
Colby T.

17:05 – 17:25 What kind of inflammatory changes can we find in different ILDs? Are they disease specific?  
Matěj R.

17:25 – 17:45 Alveolar damage and its outcomes from the pathologist’s point of view.  
Colby T.

17:45 – 18:30 Histopathologic case reports. Interactive session with voting of audience.  
Colby T., Matěj R.

FRIDAY  
20 JUNE 2014

8:30 – 9:00 Honorary Lecture: Sarcoidosis as potentially fibrosing ILD.  
Baughmann R. 25 min + 5 min Discussion

Session V – Idiopathic interstitial pneumonias  
Chairs: Wells A., Poletti V., Vašáková M.

9:00 – 9:30 Idiopathic pulmonary fibrosis.  
Diagnosis, differential diagnosis and treatment.  
Wells A. (25 min + 5 min Discussion)

9:30 – 10:00 Nonspecific interstitial pneumonia.  
Diagnosis, differential diagnosis and treatment.  
Vašáková M. (25 min + 5 min Discussion)

Costabel U. (25 min + 5 min Discussion)

10:30 – 10:50 Lymphoid primary lung disorders.  
Diagnosis, differential diagnosis and treatment.  
Poletti V. (15 min + 5 min Discussion)

10:50 – 11:15 Coffee Break

Session VI – Exogenous ILDs I  
Chairs: Nemery B., Antoniou K., Šterclová M.

Antoniou K. (30 min + 5 min Discussion)

Šterclová M. (30 min + 5 min Discussion)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:25 – 13:00</td>
<td>Rare exogenous ILDs. (ILDs caused by metals, organic dusts toxic syndrome, et al). Nemery B. (30 min + 5 min Discussion).</td>
</tr>
<tr>
<td>13:00 – 14:00</td>
<td>Lunch</td>
</tr>
<tr>
<td>14:00 – 15:00</td>
<td>Poster Session and Discussion</td>
</tr>
<tr>
<td></td>
<td>Chairs: Faculty</td>
</tr>
<tr>
<td></td>
<td><strong>Session VII – Practical/workshops – Role of bronchoscopy in diagnosis of ILDs</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Vašáková M., Poletti V.</td>
</tr>
<tr>
<td>15:00 – 15:30</td>
<td>Bronchoscopic techniques, specimen obtaining, preservation, possibilities of investigation. Vašáková M. (25 min + 5 min Discussion)</td>
</tr>
<tr>
<td>15:30 – 16:00</td>
<td>Bronchoalveolar lavage- its role in ILDs. Poletti V. (25 min + 5 min Discussion)</td>
</tr>
<tr>
<td>16:00 – 16:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td></td>
<td><strong>Session VIII – Exogenous ILDs II + Pulmonary manifestations of Connective tissue diseases (CTDs)</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Camus P., Cordeiro CR., Antoniou K.</td>
</tr>
<tr>
<td>16:30 – 17:05</td>
<td>Pneumoconioses. Diagnosis, differential diagnosis and treatment. Cordeiro CR. (30 min + 5 min Discussion)</td>
</tr>
<tr>
<td>17:05 – 17:40</td>
<td>Drug related ILDs. Diagnosis, differential diagnosis and treatment. Camus P. (30 min + 5 min Discussion)</td>
</tr>
<tr>
<td>17:40 – 18:15</td>
<td>Pulmonary manifestations of CTDs. Diagnosis, differential diagnosis and treatment. Antoniou K. (30 min + 5 min Discussion)</td>
</tr>
<tr>
<td>21 June 2014</td>
<td>SATURDAY</td>
</tr>
<tr>
<td>8:30 – 9:00</td>
<td><strong>Session IX – Molecular mechanisms of fibro-proliferative ILDs for further research and as potential therapeutic targets.</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Koenigshoff M., Crestani B., Richeldi L.</td>
</tr>
<tr>
<td>9:00 – 9:30</td>
<td>Genetic background of fibrosing ILDs. Susceptibility genes and polymorphisms. Regulators of gene expression. Petřek M. (25 min + 5 min Discussion)</td>
</tr>
<tr>
<td>9:30 – 10:00</td>
<td>Fibroproliferative healing. Pathways. Cytokines. Koenigshoff M. (25 min + 5 min Discussion)</td>
</tr>
<tr>
<td>10:00 – 10:30</td>
<td>Differences in fibroproliferative healing in exogeneous and idiopathic ILDs. Are there any? Richeldi L. (25 min + 5 min Discussion)</td>
</tr>
<tr>
<td>10:30 – 11:00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td></td>
<td><strong>Session X – Treatment of fibrotic and inflammatory ILDs. Novel approaches. Results of clinical studies.</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Costabel U., Koenigshoff M., Richeldi L.</td>
</tr>
<tr>
<td>11:00 – 11:30</td>
<td>Potential molecular targets for treatment modalities. Koenigshoff M. (25 min + 5 min Discussion)</td>
</tr>
<tr>
<td>11:30 – 12:00</td>
<td>Pirfenidone, its role in IPF treatment. Costabel U. (25 min + 5 min Discussion)</td>
</tr>
<tr>
<td>12:00 – 12:30</td>
<td>Novel drugs. Richeldi L. (25 min + 5 min Discussion)</td>
</tr>
<tr>
<td>12:30 – 12:40</td>
<td>Closing remarks. End of the course.</td>
</tr>
<tr>
<td>12:40 – 13:40</td>
<td>Lunch</td>
</tr>
</tbody>
</table>

www.ildprague2014.com
www.ildprague2014.com